New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2014
11:36 EDTIGT, MYLStocks with call strike movement; IGT MYL
International Game (IGT) July 18 call option implied volatility increased 8% to 37, Mylan (MYL) July 65 call option implied volatility increased 2% to 36 according to IVolatility.
News For IGT;MYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 31, 2015
19:48 EDTMYLMylan 35M share Secondary priced at $58.35
Subscribe for More Information
09:50 EDTMYLMylan launches generic Exforge tablets in U.S.
Subscribe for More Information
March 30, 2015
13:01 EDTMYLOptions with increasing volume
Subscribe for More Information
10:46 EDTMYLOptions with increasing implied volatility
Subscribe for More Information
10:24 EDTMYLMylan volatility up after filing to sell 35M shares for Abbott Laboratories
Subscribe for More Information
09:27 EDTMYLOn The Fly: Pre-market Movers
Subscribe for More Information
09:15 EDTMYLTeva does not rule out bigger deal if opportunity arises
Subscribe for More Information
09:02 EDTMYLMylan slips amid Abbott share sale, Teva deal for Auspex
Subscribe for More Information
06:34 EDTMYLMylan files to sell 35M shares of stock for Abbott Laboratories subsidiaries
Subscribe for More Information
March 27, 2015
18:02 EDTIGTS&P announces changes to S&P 400, 500, and 600 indices
Subscribe for More Information
17:20 EDTIGTWindstream to replace International Game in S&P 400 as of 4/6 close
07:45 EDTMYLFDA to hold a public meeting
Subscribe for More Information
07:25 EDTMYLTeva appears to be weighing transformative deal, says Bernstein
After attending Teva's (TEVA) meeting with investors, Bernstein thinks that the company is considering making a 'transformative' acquisition, although it believes that such a deal may not be imminent. The firm sees Mylan ((MYL) and the generic units of Actavis (ACT), Pfizer (PFE), and possibly Valeant (VRX) as the four logical candidates. It says that Teva can pay $81 per share for Mylan, and that a takeover of Mylan would raise Teva's EPS to about $6.50 in 2017 and $7 in 2018. Bernstein raised its price target on Teva to $69 from $60 and keeps an Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use